Abstract
Polymer based therapies offer many potential advantages in the treatment of diseases of the nervous system, and would allow delivery of therapeutic agents directly to the relevant area of brain, circumventing obstacles presented by the blood brain barrier, avoiding the side-effects often associated with systemic medication administration, and permitting much smaller doses of medication. As improvements in diagnostic procedures, particularly imaging, now provide very accurate localization of therapeutic targets in many of these conditions, it is technically feasible to deliver such agents precisely to the relevant brain region. Combined with advances in polymer sciences, there is renewed interest in focal drug delivery systems, particularly around intelligent or controlled release systems which would extend the life-span of these devices considerably. Major obstacles remain, however, particularly around the safety and biocompatibility of such materials, and the complexity of testing in clinical scenarios. We review here the current status of animal and human studies in this rapidly evolving area, addressing some of the practical obstacles and examining the range of potential applications in chronic neurological disease.
Keywords: Neurological disorders, Parkinson's disease, Alzheimer's disease, Huntington's disease, polymer, drug delivery, epilepsy, implantable devices
CNS & Neurological Disorders - Drug Targets
Title: Polymer-Based Drug Delivery Devices for Neurological Disorders
Volume: 8 Issue: 3
Author(s): A. J. Halliday and M. J. Cook
Affiliation:
Keywords: Neurological disorders, Parkinson's disease, Alzheimer's disease, Huntington's disease, polymer, drug delivery, epilepsy, implantable devices
Abstract: Polymer based therapies offer many potential advantages in the treatment of diseases of the nervous system, and would allow delivery of therapeutic agents directly to the relevant area of brain, circumventing obstacles presented by the blood brain barrier, avoiding the side-effects often associated with systemic medication administration, and permitting much smaller doses of medication. As improvements in diagnostic procedures, particularly imaging, now provide very accurate localization of therapeutic targets in many of these conditions, it is technically feasible to deliver such agents precisely to the relevant brain region. Combined with advances in polymer sciences, there is renewed interest in focal drug delivery systems, particularly around intelligent or controlled release systems which would extend the life-span of these devices considerably. Major obstacles remain, however, particularly around the safety and biocompatibility of such materials, and the complexity of testing in clinical scenarios. We review here the current status of animal and human studies in this rapidly evolving area, addressing some of the practical obstacles and examining the range of potential applications in chronic neurological disease.
Export Options
About this article
Cite this article as:
Halliday J. A. and Cook J. M., Polymer-Based Drug Delivery Devices for Neurological Disorders, CNS & Neurological Disorders - Drug Targets 2009; 8(3) . https://dx.doi.org/10.2174/187152709788680698
DOI https://dx.doi.org/10.2174/187152709788680698 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Context-dependent Action of Transforming Growth Factor β Family Members on Normal and Cancer Stem Cells
Current Pharmaceutical Design Mechanisms of Oxidative Glutamate Toxicity: The Glutamate/Cystine Antiporter System xc¯ as a Neuroprotective Drug Target
CNS & Neurological Disorders - Drug Targets Molecular Dynamics of Protein Kinase-Inhibitor Complexes: A Valid Structural Information
Current Pharmaceutical Design Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Current Pharmaceutical Design Vascular Endothelial Growth Factor in Central Nervous System Injuries – A Vascular Growth Factor Getting Nervous?
Current Neurovascular Research Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 2. Structural Analogues and Derivatives
Current Drug Targets Anti-Cancer Effects of Citalopram on Hepatocellular Carcinoma Cells Occur via Cytochrome C Release and the Activation of NF-kB
Anti-Cancer Agents in Medicinal Chemistry Oncolytic Viruses: Programmable Tumour Hunters
Current Gene Therapy Herpes Simplex Virus Vectors for Gene Delivery to a Variety of Different Cell Types
Current Gene Therapy Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism Antioxidant, Anti-Inflammatory and Cytotoxic Properties of <i>Centaurea africana</i> Lamk var. [Bonnet] M
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Advanced Micro-Nano-Bio Systems for Future Targeted Therapies
Current Nanoscience Autoimmunity and Frontotemporal Dementia
Current Alzheimer Research Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Nanoparticles: Properties and Applications in Cancer Immunotherapy
Current Pharmaceutical Design Radiogenetic Therapy: Strategies to Overcome Tumor Resistance
Current Pharmaceutical Design Use of Bimetallic Nanoparticles in the Synthesis of Heterocyclic Molecules
Current Organic Chemistry Stem Cell Therapies for Intervertebral Disc Degeneration: Immune Privilege Reinforcement by Fas/FasL Regulating Machinery
Current Stem Cell Research & Therapy IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets MicroRNA-21: From Cancer to Cardiovascular Disease
Current Drug Targets